Guangxi Wuzhou Zhongheng Group Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Guangxi Wuzhou Zhongheng Group Co., Ltd. was established in 1993 and listed on the Shanghai Stock Exchange in November 2000 (600252. SH). It is a listed company controlled by Guangxi Investment Group, a Fortune Global 500 enterprise, a national high-tech enterprise, and a national intellectual property demonstration enterprise. It ranks among the top 100 pharmaceutical industries in China and the top 100 pharmaceutical industries of the Chinese nation, and has been selected as the second batch of pilot enterprises for the integrated development of advanced manufacturing and modern service industries Enterprises under the "Guangxi Double Hundred Action" for state-owned enterprise reform. Ranked 19th on the "2021 Top 100 Chinese Traditional Chinese Medicine Enterprises Ranking". It holds 10 important subsidiaries. Among them, there are 3 national high-tech enterprises and 1 listed company (Chongqing Laimei Pharmaceutical, stock code: 300006). Zhongheng Group focuses on pharmaceutical manufacturing and health consumption, deepening and expanding its pharmaceutical research and development, traditional Chinese medicine resources, daily cosmetics, and pharmaceutical distribution businesses, forming six main business segments. We have a national level enterprise technology center, a "Key Laboratory for Deep Development and Resource Utilization of Panax notoginseng Products" awarded by the National Administration of Traditional Chinese Medicine, as well as innovative platforms such as the "Academician Zhang Boli Workstation" and the Guangxi Panax notoginseng Comprehensive Utilization Technology Key Laboratory. We cooperate with well-known universities and experts to promote the modernization and specialization of the big health industry. We have 528 drug production approval numbers, 354 patents, 24 exclusive production varieties nationwide, and 106 varieties listed in the Chinese Pharmacopoeia. The flagship product, Xueshuantong, is the earliest national patented product developed and exclusively produced by Zhongheng Group. Xueshuantong for injection (freeze-dried) has been included in the medical insurance and basic drug catalog, firmly ranking first in the treatment of cardiovascular and cerebrovascular diseases, and has won the second prize of the National Science and Technology Progress Award. The "Zhonghua" series of products is the only authorized use of the "Zhonghua" trademark in the pharmaceutical field of China. Carnaline is a nano carbon suspension injection, the only lymphatic tracer approved by CFDA in China, and a routine first-line medication for thyroid surgery in China, with a market share of over 80%. At present, Zhongheng Group has established a new development pattern of "Sanqi" full industry chain and "Chinese medicine+chemical medicine+biological medicine". Adhere to integrity and innovation, and run Hengye with perseverance. During the 13th Five Year Plan period, a total of 14.5 billion yuan in operating revenue, 2.7 billion yuan in taxes and fees paid, and over 350 million yuan in donations were achieved. In recent years, the company has won many honors such as "National Advanced Collective for Poverty Alleviation", "National May Day Labor Medal", "National exemplary organization for Employment", "National Women's Civilized Post", "National May Day Women's Model Post", "China Charity Outstanding Contribution (Enterprise) Award", "China Children's Charity Outstanding Contribution Award", "Bagui Charity Award", etc. During the 14th Five Year Plan period, Zhongheng Group will adhere to the concept of "stabilizing the basic market, cultivating growth points, focusing on high quality, and ensuring sustainability", and achieve new breakthroughs and leaps on the path of "specialization, refinement, specialty, and innovation". It will focus on strengthening the health deepening business, transforming and laying out cost leading businesses, and taking the opportunity to cultivate innovation driven businesses, striving to become a "leader in the health deepening model and a practitioner of innovative exploration models" in the field of Chinese pharmaceutical and health product manufacturing, Make due contributions to healthy China, magnificent Guangxi, industrial Wuzhou, century old Guangtou, and vibrant Guangtou. |
| Headquarter | Wuzhou City |
| Establish Date | 7/28/1993 |
| Listed Code | 600252.SH |
| Listed Date | 11/30/2000 |
| Chairman | Yang Jinhai. |
| CEO | Ni Yidong. |
| Website | www.wz-zhongheng.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
